Iara Gonçalves

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 258 citations

Medicine, Oncology, Pharmacology +15

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

Jacob P. Laubach, Fredrik Schjesvold, Mário Mariz et al. · The Lancet Oncology · 2020 · 68 citations

Medicine, Pharmacology, Pharmacotherapy +15

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · Journal of Clinical Oncology · 2020 · 34 citations

Medicine, Oncology, Pharmacotherapy +17